key: cord-0267814-n1ioivo2
authors: He, Wan-ting; Yuan, Meng; Callaghan, Sean; Musharrafieh, Rami; Song, Ge; Silva, Murillo; Beutler, Nathan; Lee, Wilma; Yong, Peter; Torres, Jonathan; Melo, Mariane; Zhou, Panpan; Zhao, Fangzhu; Zhu, Xueyong; Peng, Linghang; Huang, Deli; Anzanello, Fabio; Ricketts, James; Parren, Mara; Garcia, Elijah; Ferguson, Melissa; Rinaldi, William; Rawlings, Stephen A.; Nemazee, David; Smith, Davey M.; Briney, Bryan; Safonova, Yana; Rogers, Thomas F.; Crotty, Shane; Irvine, Darrell J.; Ward, Andrew B.; Wilson, Ian A.; Burton, Dennis R.; Andrabi, Raiees
title: Broadly neutralizing antibodies to SARS-related viruses can be readily induced in rhesus macaques
date: 2021-07-05
journal: bioRxiv
DOI: 10.1101/2021.07.05.451222
sha: 00122d28e2ea4a3a34c6d025509cbd5b78e58d55
doc_id: 267814
cord_uid: n1ioivo2

To prepare for future coronavirus (CoV) pandemics, it is desirable to generate vaccines capable of eliciting neutralizing antibody responses against multiple CoVs. Because of the phylogenetic similarity to humans, rhesus macaques are an animal model of choice for many virus-challenge and vaccine-evaluation studies, including SARS-CoV-2. Here, we show that immunization of macaques with SARS-CoV-2 spike (S) protein generates potent receptor binding domain cross- neutralizing antibody (nAb) responses to both SARS-CoV-2 and SARS-CoV-1, in contrast to human infection or vaccination where responses are typically SARS-CoV-2-specific. Furthermore, the macaque nAbs are equally effective against SARS-CoV-2 variants of concern. Structural studies show that different immunodominant sites are targeted by the two primate species. Human antibodies generally target epitopes strongly overlapping the ACE2 receptor binding site (RBS), whereas the macaque antibodies recognize a relatively conserved region proximal to the RBS that represents another potential pan-SARS-related virus site rarely targeted by human antibodies. B cell repertoire differences between the two primates appear to significantly influence the vaccine response and suggest care in the use of rhesus macaques in evaluation of vaccines to SARS-related viruses intended for human use. ONE SENTENCE SUMMARY Broadly neutralizing antibodies to an unappreciated site of conservation in the RBD in SARS- related viruses can be readily induced in rhesus macaques because of distinct properties of the naïve macaque B cell repertoire that suggest prudence in the use of the macaque model in SARS vaccine evaluation and design.

The rapid development of multiple vaccines to counter the COVID-19 pandemic caused by SARS-CoV-2 has been a triumph for science and medicine. The reason for these successes is likely due, in part, to the relative ease of inducing protective neutralizing antibodies (nAbs) in humans by immunization with the spike (S) protein, the key component of most vaccines (1) (2) (3) (4) . Different presentations of S in the vaccines induce relatively high serum nAb responses in most individuals that appear to strongly target the ACE2 receptor binding site (RBS) in the receptor binding domain (RBD) (1, [5] [6] [7] [8] [9] . Natural infection with SARS-CoV-2 targets the RBD similarly (1, [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] . A key contributor is the human VH3-53 antibody germline gene that encodes a major subset (RBS-A, Class 1) of highly potent immunodominant nAbs that require minimal somatic hypermutation (SHM) and are specific for SARS-CoV-2 (22) (23) (24) (25) . These and other nAbs to the RBS are likely responsible for driving some of the mutations found in Variants of Concern (VOCs) (23, (26) (27) (28) (29) (30) .

Here, we immunized rhesus macaques with SARS-CoV-2 S-protein to compare nAb responses between macaques and humans with a particular emphasis on the breadth of elicited neutralizing responses to sarbecoviruses and the effects of differences between the naive antibody repertoires of the two primate species on responses.

A recombinant prefusion-stabilized soluble S-protein in a saponin adjuvant (SMNP) was administered through subcutaneous injection (s.c.) in naïve rhesus macaques (RMs) (n = 8).

Since the manner of immunogen administration may shape immune responses (31) (32) (33) , two protocols were evaluated: a conventional prime-boost consisting of bolus injections (100µg) at weeks 0 and 10 for Group 1 animals (n = 4), and an escalating dose (ED) prime and bolus boost for Group 2 (n=4) (Fig. 1A) . Serum Ab responses to SARS-CoV-2 S-protein, evaluated by enzyme-linked immunosorbent assay (ELISA) (figs. S1 and S2), were detected in both groups at week 2 and, although responses at week 4 were stronger for the ED group, no major differences were found subsequently. Boost immunization at week 10 increased EC50 binding titers to the 10 3 -10 4 range for all animals, indicating a strong antibody recall response. ID50 neutralization titers showed a similar pattern where both immunization groups developed specific neutralizing antibody responses by week 4, which were enhanced by week 12, post-boost (figs. S1 and S2).

Next, we examined serum responses for cross-reactivity with SARS-CoV-1 (Fig. 1B, fig. S2 ).

Strong cross-reactive binding responses to SARS-CoV-1 S protein were observed (Fig. 1B, fig.   S2 ), as well as strong cross-neutralizing antibody responses against SARS-CoV-1 (Fig. 1C, fig.   S2 ). ID50 neutralization titers showed a modest correlation with EC50 binding titers for both SARS-CoV-2 and SARS-CoV-1 (Fig. 1D ). The elicitation of potent cross-neutralizing responses in rhesus macaques by S-protein immunization is in stark contrast to human SARS-CoV-2 natural infection, which typically results in autologous nAb responses where cross-neutralizing activity against SARS-CoV-1 is rare (Fig. 1E, fig. S3 ) (34) (35) (36) . In humans vaccinated with mRNA S-protein, we similarly found SARS-CoV-2 autologous but not SARS-CoV-1 cross-reactive nAb responses (Fig.   1E , fig. S3 ) as also described by others (37) .

To examine the role of species-specific B cell immunogenetic differences, we vaccinated a group of 5 mice twice (wk0-prime, wk3-boost) with SARS-CoV-2 S-protein and SMNP adjuvant ( fig. S4 ).

Consistent with earlier studies (38) (39) (40) , SARS-CoV-2 S protein immunization of mice elicited high titers of autologous SARS-CoV-2 nAbs; however, the SARS-CoV-1 cross-neutralizing antibody titers were significantly less than the macaque cross-nAb responses (Fig. 1E, fig. S4 ), indicating a strong species-dependent contribution to development of bnAbs to SARS-CoV-2 S protein.

We next characterized polyclonal nAb specificities generated in the macaques by measuring the binding of immune sera in the presence of three well-characterized human nAbs to SARS-CoV-2 S-protein and RBD by Bio-layer Interferometry ( fig. S5 ). These nAbs define unique epitopes on the RBD and were isolated from a COVID-19 convalescent donor (CC12.3 and CC12.19) (11, 22) and a SARS-CoV-1 donor (CR3022) (11, 41) . CC12.3 is a VH3-53 nAb targeting the ACE2 binding site and designated as RBS-A or class 1 (22) (23) (24) . CC12.19 recognizes a complex RBD epitope but competes with some non-RBD Abs (11) . CR3022 recognizes the class 4 epitope site (23, 24) .

Macaque sera bound well to S-protein in the presence of the nAbs suggesting the RBD nAb response was a minor part of the total S-response ( fig. S5 ). However, binding to RBD was strongly inhibited at week 10 by all 3 nAbs consistent with a strong response to RBD neutralizing epitopes ( fig. S5 ). The inhibition was reduced following boosting suggesting that antibody responses to B cell epitopes outside of the RBD may increase after secondary immunization (42, 43) .

To further determine the contributions of RBD-specific antibodies in polyclonal immune sera, we suggest that SARS-CoV-2 neutralization in both post-prime and post-boost macaque immune sera is dominated by RBD-specific nAb responses, but post-boost nAbs to non-RBD S epitopes or trimer-dependent RBD epitopes may minimally contribute to neutralization.

Since macaque sera competed strongly with human RBD nAbs and neutralization was largely RBD directed, we investigated other sarbecoviruses by engrafting the RBD from those viruses onto the SARS-CoV-2 backbone (44) (45) (46) . We chose the 3 sarbecoviruses, WIV1, RaTG13 and pang17, which use ACE2 receptor for cell entry and are phylogenetically related to SARS-CoV-2 and SARS-CoV-1 ( Fig. 2A, fig. S7 ). The week-14 macaque immune sera consistently and potently neutralized all three chimeric pseudoviruses ( Fig. 2B) with the WIV1 chimera being most effectively neutralized averaged over all animals. COVID-19 sera only neutralized the closely related RaTG13 chimera at a lower level than the macaque sera (Fig. 2B) . Spike mRNA human immune sera showed moderate neutralization against WIV1 and RaTG13 chimeras and sporadic neutralization of the pang17 chimera. The results suggest the macaque immune sera targets more conserved RBD regions on sarbecoviruses than sera from human infection or human mRNA vaccination. The fine details of this cross-reactivity are consistent with the relatedness of these viruses to SARS-CoV-1 and SARS-CoV-2. RaTG13 RBD is closer to SARS-CoV-2 ( fig S7) and is neutralized more efficiently by COVID-19 sera in which neutralization is predominantly RBD directed. WIV1 is closer to SARS-CoV-1 and is neutralized more potently by the macaque immune sera that neutralizes SARS-CoV-1 more effectively than SARS-CoV-2.

Next, we compared the macaque, human COVID-19 and mRNA vaccine sera for neutralization of SARS-CoV-2 incorporating key mutations from current SARS-CoV-2 VOCs, B.1.1.7 (alpha), B.1.351 (beta), P.1 (gamma) and B.1.617 (delta) (Fig. 2C) (9, 23, 28, 29) . While human COVID-19 and vaccine sera showed significant loss of neutralization activity against point mutants and SARS-CoV-2 VOCs, macaque immune sera maintained neutralizing activity (Fig. 2D ). This result is again consistent with macaque sera targeting more conserved regions of the S-protein and apparently thereby yielding antibodies with less sensitivity to known escape mutations.

We isolated mAbs from two animals (K288 and K398) by sorting antigen-specific single B cells using SARS-CoV-2 and SARS-CoV-1 S proteins as baits ( Fig 3A) . Briefly, CD19 + CD20 + IgG + IgMdouble positive B cells for SARS-CoV-2 and SARS-CoV-1 S-protein were sorted from peripheral blood mononuclear cells (PBMCs) from immunized animals. Paired heavy (HC) and light (LC) chain sequences from single B cells were recovered and 40 mAbs were expressed (Fig. 3B) . BLI binding revealed that all but 6 mAbs exhibited binding to SARS-CoV-2 and/or SARS-CoV-1 Sprotein (Fig. 3B, fig. S8 ). 14 of 34 mAbs showed cross-neutralization of SARS-CoV-1 and SARS-CoV-2, while 3 mAbs neutralized only SARS-CoV-2 (Fig. 3B, fig. S8 ). Unexpectedly, most crossneutralizing mAbs were more potent against SARS-CoV-1 than SARS-CoV-2 (Fig 3B, fig. S8 ). 17 of 34 mAbs bound S-protein only and not RBD or NTD, but none showed neutralization. All neutralizing mAbs (except one NTD-specific) bound strongly to RBDs (Fig. 3B, fig. S8 ). Overall, these results are consistent with the polyclonal nAb data described above (Fig. 1) and show that macaque immunization here with S-protein generates potent SARS-CoV-1/2 nAb responses. We next extended the neutralization studies to a range of sarbecovirus RBD chimeric SARS-CoV-2 pseudoviruses (Fig. 3C, fig. S8 ). Most of the mAbs that showed potent SARS-CoV1/2 neutralization also neutralized WIV1 but activity against RaTG13 and pang17 was more sporadic.

Some mAbs did neutralize all 5 sarbecoviruses tested, albeit with relatively lower neutralization potency (Fig. 3C, fig. S8 ). The cross-reactivity of mAbs was also confirmed by BLI binding studies with monomeric RBDs derived from spike of WIV1, RatG13 and Pang17 sarbecoviruses ( fig. S9 ).

We also tested neutralization by these cross-reactive mAbs against SARS-CoV-2 VOCs and key mutants. Consistent with the macaque sera mapping above, the mAbs were generally equally effective against variants (Fig. 3 , D and E). In contrast, CC12.1 isolated from a COVID-19 human donor showed complete loss of neutralizing activity with the SARS-CoV-2 K417N variant and B.1.351 and P.1 circulating escape variants (Fig. 3 , D and E).

We next sought to determine molecular differences between mAbs that would explain their differential neutralization. First, we analyzed the mAb sequences and found that they utilized a range of germline gene families with strong enrichment for IGHV3-73 and, to some extent, IGHV3-50 and IGHV5-15, heavy chain germline genes (Fig. 4A, fig. S10 ). None of the IGHV3-73 Abs from either animal (K288 and K398) were clonal members, suggesting independent selection of this gene family with common VH-germline gene features ( fig. S10) . Notably, the rhesus macaque IGHV3-73 germline gene is closely related in sequence to human IGHV3-53 and IGHV3-66 genes, commonly utilized by human SARS-CoV-2 nAbs isolated from natural infection and vaccination, that initially suggested the possibility of convergent modes of RBD site epitope recognition (fig. S11) (9, 20, 22, 23, 25) . Some cross-nAb members were encoded by non-IGHV3-73 gene families (Fig. 4, A and B, fig. S10 ). However, most of the IGHV3-50 and IGHV5-15 encoded antibodies were non-neutralizing, including some clonally expanded antibody lineages isolated from animal K398 (Fig. 4, A and B, fig. S10 ). The CDRH3 lengths ranged from 9-23 amino acid residues (Fig. 4C, fig. S10 ) with nAbs possessing relatively longer CDRH3 loops (median = 17aa) than non-nAbs (median = 12aa). Two nAbs used the longest CDRH3 of 23aa residues (fig. S10). The nAbs had relatively lower SHM compared to non-nAbs (median nt SHMs; neutralizing = 10, non-neutralizing = 14.5) (Fig. 4C, fig. S10 ).

We next mapped the epitopes recognized by the macaque RBD nAbs by BLI competition with CC12.3, CC12.19, CR3022 as well as S309 that recognizes the class 3 epitope site (23, 24) . All 11 macaque IGHV3-73-encoded SARS-CoV-1/2 nAbs strongly competed with VH3-53 CC12.3 nAb, and many showed moderate to weak competition with CR3022 (Fig. 4D, fig. S12 ). Two nAbs, K398.17 and K398.18, strongly competed with CC12.19 nAb, with K398.18 antibody also competing with S309 (47) . Two nAbs, K398.25 and K398.16 competed strongly with CR3022 that targets the class 4 site (Fig. 4D, fig. S12 ). The mAbs showing the greatest overall pansarbecovirus cross-neutralization breadth were those competing with CR3022 or CC12.19.

We turned next to structural studies to gain a better understanding of the neutralizing crossreactivity. Single-particle, negative-stain electron microscopy (nsEM) was used to image representative macaque nAb Fabs, K288.2, K398.22, K398.8 (VH3-73), K398.18 (VH4-149), K398.25 (VH1-105) and K398.16 (VH5-15) with SARS-CoV-1/2 S-proteins. NsEM confirmed binding of all 6 nAbs to spike RBD where the cross-nAbs encoded by various germline V-genes interacted with the RBD via distinct binding modes (Fig. 5A, fig. S13 ). The binding modes were largely similar for SARS-CoV-2 and SARS-CoV-1 S-proteins with some exceptions (Fig. 5 , A and B, fig. S13 ). We compared reconstructions of two macaque IGVH3-73 and two human IGVH3-53 nAbs and noted differences in the angles of approach to the SARS-CoV-2 RBD; the macaque cross nAbs interacted with the RBD from a more lateral angle compared to the two human nAbs with a more perpendicular approach angle close to the spike 3-fold axis (Fig. 5C ).

To investigate the binding of the potent macaque VH3-73 nAbs in greater detail, we determined crystal structures of K288.2 and K398.22 antibody Fabs with SARS-CoV-2 RBD at 2.3 Å and 1.95 Å resolution, respectively (Fig. 6 , A to H, tables S1 and S2). Both nAbs bind a novel epitope where the heavy-chain dominates the interaction as expected from enrichment of IGVH3-73 and its pairing with different light chains (Fig 6, A to H, figs. S10, S14, S15). However, the IGHV3-73encoded macaque nAbs and IGHV3-53 human nAbs interact differently with the RBD; both interact with the ACE2 binding site but at opposite ends (Fig 6, B and F, fig. S14 , B and C). For the human nAbs, the germline-encoded CDRH1 and CDRH2 both contribute substantially to RBD recognition (18, 22) , the macaque nAbs predominantly rely on CDRH2 and less on CDRH1 ( S14C ). Most of the CDRH2-mediated epitope recognition by the macaque bnAbs derives from germline residues that interact with a conserved sarbecovirus RBD region (Fig 6, I and K, fig. S1 ).

The human and macaque germlines also differ at critical CDRH1 residues. The human IGHV3-53 germline encodes a CDRH1 32 NY 33 motif critical for RBD recognition (fig. S14, C and D) (22) , whereas macaque IGHV3-73 antibodies bind to a different RBD region where only VH E33 in CDRH1 of K288.2 and K398.22 interact (Fig. 6D, H, fig. S14 , C and E). Thus, immunodominant IGHV3-73-encoded macaque nAbs target more highly conserved RBD residues across hACE2utilizing sarbecoviruses thereby providing a structural basis for their broad cross-reactivity (Fig.   6K, fig. S16 ). Preclinical approaches to vaccine development rely heavily on immunization of animal models with candidate immunogens. Indeed, for the current COVID-19 vaccines, strong nAb responses were first observed to the SARS-CoV-2 S-protein presented on several platforms in a number of animal models (38-40, 44, 48-55) . The nAb responses were protective in rhesus macaque models of SARS-CoV-2 infection (5, 44, 49, 56, 57) and clinical studies subsequently identified nAbs as a strong correlate of protection in humans (58) (59) (60) . Most macaque studies focused on the potency of nAb responses to the original Wuhan or Washington strains of SARS-CoV-2 but, more recently, greater interest has centered on the breadth of responses to divergent viruses. One recent study (49) investigated use of different adjuvants with stabilized recombinant SARS-CoV-2 S proteins presented on nanoparticles in macaques and noted nAb responses of varying potency and neutralization breadth. One adjuvant produced only a 4.5-fold reduction in neutralizing titer against the B.1.351 variant, whereas another produced a 16-fold reduction. Another macaque study (44) , which used RBD on a nanoparticle with a strong adjuvant as well as mRNA, induced very high nAb titers to SARS-CoV-2 with some reduction against VOCs. In addition, sera neutralized SARS-CoV-1 and related sarbecoviruses, albeit with reduced potency.

Here, we immunized macaques with S-protein using a strong saponin-based adjuvant and generated potent and broad nAb responses. Unlike other studies, nAb responses were equally potent against SARS-CoV-2 and SARS-CoV-1. Whereas the immunodominant human nAb RBS-A/Class 1 response to S-protein largely utilizes the VH3-53 germline gene segment, the immunodominant macaque response leads to a strong VH3-73 response that involves a different epitope and different approach angle to interact with the RBD. The different binding mode allows for SARS-CoV-1/SARS-CoV-2 cross-neutralization and retention of neutralization of VOCs.

A number of lessons can be learned from this study. First, one cannot necessarily assume that because immunization of macaques leads to SARS-CoV-2 cross-neutralizing responses that the same immunogen will give similar results in humans. Differences between human and rhesus (49) Fourth, given the important response differences between human and the closely phylogenetically related rhesus macaque, continued exploration of human antibody-repertoire based model systems such as humanized mice (69) (70) (71) and specific antibody knock-in mice (67, 72, 73) should be a priority for immunogen evaluation in rational vaccine design approaches. These findings suggest caution in the use of macaque models in SARS vaccine evaluation but also provide valuable information that may ultimately assist in pan-CoV vaccine design. 

Figs. S1 to S16 Tables S1 to S2

References 75-94 were performed using a Mann-Whitney two-tailed test, (**p <0.01; ****p < 0.0001; ns-p >0.05).

F. Neutralization of SARS-CoV-2 by post-prime (wk10) and post-boost (wk14) macaque immune sera and the corresponding anti-RBD antibody-depleted sera (RBD-depleted). Anti-RBD polyclonal antibodies in the immune sera were depleted by adsorption on recombinant monomeric RBD and the depleted sera were tested for SARS-CoV-2 neutralization. The SARS-CoV-2 ID50 neutralizing antibody titers for untreated and RBD-depleted sera were compared by Mann-Whitney two-tailed test, (**p <0.01; ****p < 0.0001). donors. The crystal structures of the respective nAbs were docked into EM density maps. The RBD, S1 and S2 subunits of SARS-CoV-2 S protein are labelled. The macaque nAbs approach spike RBD from the side and the two human nAbs approach at a more perpendicular angle close to the spike 3-fold axis. Convalescent serum samples were collected based on COVID-19 diagnosis regardless of gender, race, ethnicity, disease severity, or other medical conditions. All human donors were assessed for medical decision-making capacity using a standardized, approved assessment, and voluntarily gave informed consent prior to being enrolled in the study.

The mice and rhesus macaque animal studies were approved and carried out in accordance with 

To generate the expression plasmids for soluble S ectodomain proteins from SARS-CoV-1 (residues 1-1190; GenBank: AAP13567) and SARS-CoV-2 (residues 1-1208; GenBank: After resting at room temperature for 30 mins, the mixture was poured into 1L HEK293F cells.

The supernatant was centrifuged and filtered with 0.22 μm membrane to a glass bottle 5 days post transfection.

To purify the mAbs, Expi293 supernatant was loaded on to Protein A Sepharose (GE Healthcare) for 2h at room temperature or 4°C overnight. After incubation, the Protein A Sepharose was loaded into Econo-Pac columns (BioRad #7321010). 1 column volume of PBS was used to wash away nonspecific protein. To elute the antibody, 0.2 M citric acid (pH 2.67) was briefly mixed with Protein A Sepharose and then dripped into 2M Tris Base to neutralize the protein solution. The antibody solution was buffer exchanged into PBS using 30K Amicon tubes (Millipore, UFC903008). To purify the His-tagged proteins, HEK293F supernatant were loaded on to HisPur Ni-NTA Resin (Thermo Fisher). Three bed volumes of wash buffer (25 mM Imidazole, pH 7.4) were used to wash away the nonspecific binding proteins before the elution step. To elute the purified proteins from the column, 25 mL of elution buffer (250 mM Imidazole, pH 7.4) was loaded to the column at slow gravity speed (~4 sec/drop). The purified proteins were buffer exchanged into PBS using Amicon tubes. For further purification, the proteins were subjected to size exclusion chromatography using Superdex 200 (GE Healthcare). Endotoxin from the SARS-CoV-2 spike protein immunogen was removed using Pierce™ High-Capacity Endotoxin Removal Resin (#88270) following manufacturer's directions. Briefly, 50 µL of beads were washed twice and resuspended in 1 mL of filtered PBS. 500 µL of protein (2 mg/mL) was added to the resin and incubated at 4°C overnight on a rocking incubator. Protein and beads were passed through a 0.22 µm spin filter. Endosafe nexgen-MCS (Charles River) and Endosafe LAL cartridges (Charles River #PTS201F) were used to measure endotoxin levels. An endotoxin level below 10 EU/mL was used for the immunizations.

To generate HeLa-hACE2 cells, the human ACE2 lentivirus was transduced into HeLa cells. To produce the ACE2 lentivirus, the pBOB-hACE2 plasmid was co-transfected into HEK293T cells 

To generate the pseudoviruses, the MLV-gag/pol and MLV-CMV-Luciferase plasmids were co- 

To test the inhibition of pseudovirus infection by serum or mAbs, we used the stable cell line 

Binding of NHP mAbs to SARS-CoV-1, SARS-CoV-2 spike proteins and truncated proteins was analyzed on an Octet RED384 system using a Protein A biosensor (18-5010, Sartorius) to capture the mAbs. 10 μg/mL of each NHP mAbs were loaded on the hydrated biosensor for 60s.

Biosensors were subsequently moved into blank buffer (1x PBS + 0.1% Tween 20) for 60s to remove unbound protein and provide a baseline. The biosensors were moved to immerse in the protein solutions with 200 nM spike/truncated proteins for 120s to acquire an association signal.

To monitor disassociation, the biosensors were moved into blank buffer for 240s. All proteins and mAbs were diluted with 1x PBS + 0.1% Tween 20.

In-tandem epitope binning was carried out using the Octet RED384 in order to distinguish binding epitopes of mAbs from each other or from human mAbs or from hACE2-Fc. 100 nM of His-tagged SARS-CoV2-RBD protein antigens were captured using Anti-HIS (HIS2) biosensors Sartorius) . The biosensor was loaded with antigen for 5 min and then moved into the mAbs at saturating concentration of 100 µg/mL for 10 min. The biosensors were then moved into competing mAbs at a concentration of 25 µg/mL for 5 min to measure binding in the presence of saturating antibodies. All reactions were done in 1x PBS + 0.1% Tween 20.

To inspect the binding epitope of the NHP sera compared with known human SARS-CoV-2 mAbs or hACE2-FC, we did in-tandem epitope binning experiments using the Octet RED384 system. 

The spike proteins and truncated proteins were randomly biotinylated using an EZ-Link NHS-PEG Solid-Phase Biotinylation Kit (Thermo Scientific #21440). The reagent in each tube were dissolved with 10 μL DMSO into stock solution. For the working solution, 1 μL stock solution was diluted by 170 μL water freshly before use. The spike protein or truncated proteins were concentrated to 7-9 mg/mL using Amicon tubes in PBS before biotinylation. 3 μL of working solution was added into each 30 μL protein aliquot and incubated on ice for 3 h. The reaction ended by buffer-exchanging the protein into PBS. The biotinylated proteins were evaluated by BioLayer Interferometry.

To generate biotinylated spike probes for B cell sorting, the coronavirus spike was constructed with an Avi-tag at the C-terminus. The Avi-tagged spike proteins were concentrated to 7-9 mg/mL in TBS before the biotinylation reaction using BirA Biotin-Protein Ligase Reaction Kit (Avidity)

following manufacturer's instructions. Briefly, for each reaction, 50 μL of protein solution, 7.5 μL of BioB Mix, 7.5 μL of Biotin200, and 5 μL of BirA ligase (3 mg/mL) were added in PCR tubes and mixed thoroughly. After incubating on ice for 3 h, the biotinylated protein was purified by sizeexclusion chromatography. The biotinylated proteins were evaluated by BioLayer Interferometry using the SA biosensor.

The sorting strategy of antigen-specific memory B cells was described in previous papers (78) (79) (80) . The sorting process was performed in a 96-well format. To enrich for antigen-specific memory IV Reverse Transcriptase (Thermo Fisher), dNTPs (Thermo Fisher), random hexamers (Gene Link), Ig gene-specific primers, DTT, and RNAseOUT (Thermo Fisher), were used in the lysis buffer containing Igepal (Sigma) to carry out reverse transcription PCR as described previously (23) . To amplify IgG heavy and light chain variable regions, cDNA of each single cell was used as a template in two rounds of nested PCR reactions using Hot Start DNA Polymerases (Qiagen, Thermo Fisher) and rhesus macaque primers as described previously (80) . The PCR products were purified with SPRI beads according to manufacturer's instructions (Beckman Coulter).

Purified DNA fragments of heavy and light chain variable regions were subsequently cloned into expression vectors encoding human IgG1, and Ig kappa/lambda constant domains, respectively, using Gibson assembly (NEB, E2621L) according to the manufacturer's instructions. Paired heavy and light chain were sequenced and analyzed using the rhesus macaque (Macaca mulatta) germline database from (62) . The paired plasmids were co-transfected into 293Expi cells for antibody expression.

To generate the Fab of an IgG, a stop codon was inserted in the heavy chain constant region at "KSCDK*". The truncated heavy chains were co-transfected with the corresponding light chains in 293Expi cells to produce the Fab. The supernatants were harvested 4 days post transfection.

Fabs were purified with CaptureSelect™ CH1-XL MiniChrom Columns (#5943462005).

Supernatants were loaded onto columns using an Econo Gradient Pump (Bio-Rad #7319001)

Following a wash with 1x PBS, Fabs were eluted with 25 mL of 50 mM acetate (pH 4.0) and neutralized with 2 M Tris Base. The eluate was buffer exchanged with 1x PBS in 10K Amicon tubes (Millipore, UFC901008) and filtered with a 0.22 µm spin filter.

Spike protein was complexed with Fab at three times molar excess per trimer and incubated at room temperature for 30 mins. Complexes were diluted to 0.02mg/ml in 1x Tris-buffered saline and 3µl applied to a 400mesh Cu grid, blotted with filter paper, and stained with 2% uranyl formate.

Micrographs were collected on a ThermoFisher Tecnai Spirit microscope operating at 120kV with a FEI Eagle CCD (4k) camera at 52,000 magnification using Leginon automated image collection software (81) . Particles were picked using DogPicker (82) and 3D classification was done using Relion 3.0 (83).

The coding sequence for receptor binding domain (RBD; residues 333-529) of the SARS-CoV-2 spike (S) protein was synthesized and cloned into a customized pFastBac vector (84) , which was designed to fuse an N-terminal gp67 signal peptide and C-terminal His6-tag to the target protein.

To express the RBD protein, a recombinant bacmid DNA was generated from the sequencing- 

Heavy chain sequences of neutralizing and non-neutralizing antibodies collected from animals K398 and K288 were processed using DiversityAnalyzer tool (92) . IGHV, IGHD, and IGHJ genes of rhesus monkey (Macaca mulatta) described in (62) were used as the database of germline immunoglobulin genes. For each heavy chain sequence, the number of SHMs was computed as the number of differences in the V segment with respect to the closest IGHV gene from the database. Phylogenetic trees derived from heavy chain sequences of antibodies collected from animals K398 and K288 were constructed using ClusterW2 tool (93) and visualized using Iroki tool (94) . The IGHV gene usage for each macaque cross-nAb is indicated. The EM 3D reconstructions of Fab and S-protein complexes were generated from nsEM 2D class average images shown for each mAb, under 3D reconstruction models. The spike S1 and S2 subunits and RBD are labelled for representative cross-nAb, K288.2. 

Viral targets for vaccines against COVID-19

SARS-CoV-2 Vaccines: Status Report

SARS-CoV-2 vaccines in development

Preliminary identification of potential vaccine targets for the COVID-19 coronavirus (SARS-CoV-2) based on SARS-CoV immunological studies

Immunogenicity of clinically relevant SARS-CoV-2 vaccines in nonhuman primates and humans

An mRNA vaccine against SARS-CoV-2 -Preliminary report

Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine

Humoral immune response to circulating SARS-CoV-2 variants elicited by inactivated and RBD-subunit vaccines

mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants

Convergent antibody responses to SARS-CoV-2 in convalescent individuals

Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model

Broad neutralization of SARS-related viruses by human monoclonal antibodies

Human neutralizing antibodies elicited by SARS-CoV-2 infection

A human neutralizing antibody targets the receptor-binding site of SARS-CoV-2

Structurally resolved SARS-CoV-2 antibody shows high efficacy in severely infected hamsters and provides a potent cocktail pairing strategy

Potently neutralizing and protective human antibodies against SARS-CoV-2

A noncompeting pair of human neutralizing antibodies block COVID-19 virus binding to its receptor ACE2

Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability

Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail

Structures of Human Antibodies Bound to SARS-CoV-2 Spike Reveal Common Epitopes and Recurrent Features of Antibodies

Potent neutralizing antibodies against SARS-CoV-2 identified by highthroughput single-cell sequencing of convalescent patients' B cells

Structural basis of a shared antibody response to SARS-CoV-2

Structural and functional ramifications of antigenic drift in recent SARS-CoV-2 variants. bioRxiv

SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies

Stereotypic neutralizing VH antibodies against SARS-CoV-2 spike protein receptor binding domain in patients with COVID-19 and healthy individuals

SARS-CoV-2 escape in vitro from a highly neutralizing COVID-19 convalescent plasma. bioRxiv

Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants

SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma. bioRxiv

SARS-CoV-2 Viral Variants-Tackling a Moving Target

Antibody Resistance of SARS-CoV-2 Variants B.1.351 and B.1.1.7

Slow delivery immunization enhances HIV neutralizing antibody and germinal center responses via modulation of immunodominance

Engineered immunogen binding to alum adjuvant enhances humoral immunity

Sustained antigen availability during germinal center initiation enhances antibody responses to vaccination

Lack of cross-neutralization by SARS patient sera towards SARS-CoV-2

Cross-reactive antibody response between SARS-CoV-2 and SARS-CoV infections. bioRxiv

Cross-reactive serum and memory B-cell responses to spike protein in SARS-CoV-2 and endemic coronavirus infection

mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection

Adjuvanted SARS-CoV-2 spike protein elicits neutralizing antibodies and CD4 T cell responses after a single immunization in mice

Potent Neutralization Antibodies Induced by a Recombinant Trimeric Spike Protein Vaccine Candidate Containing PIKA Adjuvant for COVID-19

A single immunization with spike-functionalized ferritin vaccines elicits neutralizing antibody responses against SARS-CoV-2 in mice

Human monoclonal antibody combination against SARS coronavirus: synergy and coverage of escape mutants

Defining B cell immunodominance to viruses

Disassembly of HIV envelope glycoprotein trimer immunogens is driven by antibodies elicited via immunization. bioRxiv

Neutralizing antibody vaccine for pandemic and pre-emergent coronaviruses

Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses

A SARS-like cluster of circulating bat coronaviruses shows potential for human emergence

Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody

Mosaic nanoparticles elicit cross-reactive immune responses to zoonotic coronaviruses in mice

Adjuvanting a subunit COVID-19 vaccine to induce protective immunity

Vaccination with SARS-CoV-2 spike protein and AS03 adjuvant induces rapid anamnestic antibodies in the lung and protects against virus challenge in nonhuman primates

S-Trimer, a COVID-19 subunit vaccine candidate, induces protective immunity in nonhuman primates

SARS-CoV-2 spike glycoprotein vaccine candidate NVX-CoV2373 immunogenicity in baboons and protection in mice

SARS-CoV-2 ferritin nanoparticle vaccines elicit broad SARS coronavirus immunogenicity. bioRxiv

Elicitation of potent neutralizing antibody responses by designed protein nanoparticle vaccines for SARS-CoV-2

Evaluation of the mRNA-1273 Vaccine against SARS-CoV-2 in Nonhuman Primates

Immune correlates of protection by mRNA-1273 immunization against SARS-CoV-2 infection in nonhuman primates. bioRxiv

Correlates of protection against SARS-CoV-2 in rhesus macaques

Correlates of protection from SARS-CoV-2 infection

Neutralizing antibodies correlate with protection from SARS-CoV-2 in humans during a fishery vessel outbreak with a high attack rate

SARS-CoV-2 infection rates of antibody-positive compared with antibodynegative health-care workers in England: a large, multicentre, prospective cohort study (SIREN)

Commonality despite exceptional diversity in the baseline human antibody repertoire

Rhesus and cynomolgus macaque immunoglobulin heavy-chain genotyping yields comprehensive databases of germline VDJ alleles

HIV-1 VACCINES. Priming a broadly neutralizing antibody response to HIV-1 using a germline-targeting immunogen

Nucleic acid delivery of immune-focused SARS-CoV-2 nanoparticles drive rapid and potent immunogenicity capable of single-dose protection. bioRxiv

Immunogenicity of Stabilized HIV-1 Envelope Trimers with Reduced Exposure of Non-neutralizing Epitopes

Glycan masking focuses immune responses to the HIV-1 CD4-binding site and enhances elicitation of VRC01-Class precursor antibodies

Tailored immunogens direct affinity maturation toward HIV neutralizing antibodies

The functions of SARS-CoV-2 neutralizing and infection-enhancing antibodies in vitro and in mice and nonhuman primates. bioRxiv

Complete humanization of the mouse immunoglobulin loci enables efficient therapeutic antibody discovery

High-affinity IgG antibodies develop naturally in Ig-knockout rats carrying germline human IgH/Igkappa/Iglambda loci bearing the rat CH region

Mice with megabase humanization of their immunoglobulin genes generate antibodies as efficiently as normal mice

Induction of HIV neutralizing antibody lineages in mice with diverse precursor repertoires

Human Ig knockin mice to study the development and regulation of HIV-1 broadly neutralizing antibodies

Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor

Statistical analysis was performed using Graph Pad Prism 8 for Mac, Graph Pad Software

Data were considered statistically significant at p < 0.05. serum is calculated with the formula: [Percent (%) depletion = 1-(BLI binding response of the RBD-depleted immune sera / BLI binding response of the untreated immune sera) X 100] sequences of the macaque IGHV3-73 germline gene and the closest human germline genes were used to generate the phylogenetic tree. (C) Amino-acid sequence alignment of macaque IGHV3-73 germline V-gene with the 10 closest human germline genes. The human germline genes are arranged in the order of their relatedness

Paratope residues of IGHV3-53 antibodies targeting SARS-CoV-2 in the canonical mode (22) as well as macaque IGHV3-73 antibodies in this study are highlighted in yellow. Although the two germline sequences are similar (~90% sequence identity), the critical RBD-interacting human IGHV3-53 'NY' motif (underlined) is replaced by 'YE' in macaque IGHV3-73 and does not bind in the same mode

22 is used to represent the macaque IGHV3-73 antibodies and CC12.1 for human IGHV3-53 antibodies (PDB 6XC2). (C-E) Detailed interactions between SARS-CoV-2 RBD (white) and the CDRH1 'NY' motif of a human IGHV3-53 antibody CC12.1 (PDB 6XC2) and CDRH1 'NE' motif of macaque IGHV3-73 antibody K398.22. Interactions of corresponding (D) CC12.1 and (E) K398.22 CDRH1 residues with RBD are indicated

REFERENCES 75

A protective broadly cross-reactive human antibody defines a conserved site of vulnerability on beta-coronavirus spikes. bioRxiv

Pre-fusion structure of a human coronavirus spike protein

Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation

Recombinant HIV envelope trimer selects for quaternary-dependent antibodies targeting the trimer apex

Efficient generation of monoclonal antibodies from single human B cells by single cell RT-PCR and expression vector cloning

Isolation and structure of an antibody that fully neutralizes isolate SIVmac239 reveals functional similarity of SIV and HIV glycan shields

Automated molecular microscopy: the new Leginon system

DoG Picker and TiltPicker: software tools to facilitate particle selection in single particle electron microscopy

RELION: implementation of a Bayesian approach to cryo-EM structure determination

A highly conserved neutralizing epitope on group 2 influenza A viruses

A highly conserved cryptic epitope in the receptor binding domains of SARS-CoV-2 and SARS-CoV

Processing of X-ray diffraction data collected in oscillation mode

Integration, scaling, space-group assignment and post-refinement

Phaser crystallographic software

Repertoire Builder: high-throughput structural modeling of B and T cell receptors

PHENIX: a comprehensive Python-based system for macromolecular structure solution

Features and development of Coot

Reconstructing Antibody Repertoires from Error-Prone Immunosequencing Reads

Clustal W and Clustal X version 2.0

Iroki: automatic customization and visualization of phylogenetic trees

We thank all the human cohort participants for donating samples.